Anixa Biosciences (NASDAQ:ANIX) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Anixa Biosciences (NASDAQ:ANIX) posted its quarterly earnings data on Wednesday. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.03, FiscalAI reports.

Anixa Biosciences Stock Performance

NASDAQ:ANIX traded down $0.05 during trading hours on Wednesday, reaching $2.35. The company’s stock had a trading volume of 111,064 shares, compared to its average volume of 139,720. The firm has a market capitalization of $78.80 million, a price-to-earnings ratio of -7.12 and a beta of 0.59. The firm has a 50-day simple moving average of $2.79 and a 200-day simple moving average of $3.13. Anixa Biosciences has a 1 year low of $2.35 and a 1 year high of $5.46.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ANIX. Wall Street Zen cut shares of Anixa Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. D. Boral Capital reiterated a “buy” rating and issued a $10.00 target price on shares of Anixa Biosciences in a research report on Wednesday, April 8th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Anixa Biosciences has an average rating of “Hold” and an average target price of $8.50.

Hedge Funds Weigh In On Anixa Biosciences

A number of large investors have recently added to or reduced their stakes in ANIX. 683 Capital Management LLC bought a new stake in Anixa Biosciences in the 4th quarter worth $355,000. ExodusPoint Capital Management LP bought a new stake in Anixa Biosciences in the 4th quarter worth $293,000. Susquehanna International Group LLP grew its holdings in Anixa Biosciences by 378.4% in the 3rd quarter. Susquehanna International Group LLP now owns 80,387 shares of the company’s stock worth $265,000 after acquiring an additional 63,584 shares during the last quarter. Virtu Financial LLC bought a new stake in Anixa Biosciences in the 4th quarter worth $161,000. Finally, State Street Corp grew its holdings in Anixa Biosciences by 32.0% in the 4th quarter. State Street Corp now owns 159,040 shares of the company’s stock worth $496,000 after acquiring an additional 38,540 shares during the last quarter. Hedge funds and other institutional investors own 29.13% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.